Gene Delivery in Neuro-Oncology

Karan Dixit*, Priya Kumthekar

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Purpose of Review: Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults with a dismal prognosis despite aggressive multimodal management thus novel treatments are urgently needed. Gene therapy is a versatile treatment strategy being investigated in multiple cancers including GBM. In gene therapy, a variety of vectors or “carriers” are used to deliver genes designed for different anti-tumoral effects. Gene delivery vehicles and approaches to treatment will be addressed in this review. Recent Findings: The most commonly studied vectors are viral based, however, driven by advances in biomedical engineering, mesenchymal and neural stem cells, as well as multiple different types of nanoparticles have been developed to improve tumor tropism and also increase gene transfer into tumor cells. Different genes have been studied including suicide genes, which convert non-toxic prodrug into cytotoxic drug; immunomodulatory genes, which stimulate the immune system; and tumor suppressor genes which repair the defect that allow cells to divide unchecked. Summary: Gene therapy may be a promising treatment strategy in neuro-oncology as it is versatile and flexible due to the ability to tailor vectors and genes for specific therapeutic activity. Pre-clinical studies and clinical trials have demonstrated feasibility and safety of gene therapy; however, further studies are required to determine efficacy.

Original languageEnglish (US)
Article number69
JournalCurrent oncology reports
Issue number11
StatePublished - Nov 1 2017


  • Gene therapy
  • Glioblastoma
  • High-grade glioma
  • Nanoparticles
  • Stem cells
  • Viral vectors

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Gene Delivery in Neuro-Oncology'. Together they form a unique fingerprint.

Cite this